Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: NSABP B-43: A Phase III Clinical Trial Comparing Trastumumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy

 


NSABP B-43: A Phase III Clinical Trial Comparing Trastumumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy


Trial Focus

Breast Cancer

Objective

         This is a clinical trial of Trastuzumab added to breast radiation therapy. Trastuzumab is an investigational treatment.

IRB Protocol #

08-1266

Trial Status

Archived

Principle Investigator

NICOLE KOUNALAKIS

Sponsor

NSABP

Contact

BRITTANY HICKS at (720)848-0657 or BRITTANY.HICKS@UCDENVER.EDU

Location

Alamosa Shaw Regional Cancer Center (Vail) ST. MARYS HOSPITAL - G.J. University of Colorado Hospital Valley View Hospital Alamosa Shaw Regional Cancer Center (Vail) ST. MARYS HOSPITAL - G.J. University of Colorado Hospital Valley View Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last up to 3-6 weeks. A follow up period will consist of clinic visits. // Eligibility criteria : includes but is not limited to 18 years or olderEligibility criteria : includes but is not limited to 18 years or older